TLX compared with BZAI: revenue, margins and what each company keeps, and the suppliers and customers both name

TLXTelix Pharmaceuticals Ltd

Mkt capRevenueRevenue

BZAIBlaize Holdings, Inc.

Mkt capRevenueRevenue

Compare

TLXTelix Pharmaceuticals Ltd

BZAIBlaize Holdings, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

TLX1 of 4 reports

Reportimpliedrealized× implied

Oct 21 '26—▼−10.13%—

BZAI

2 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±24.6%▼−49.31%×2.00

May 15 '26±18.0%▼−25.99%×1.44

= impliedTLX realized, solidBZAI realized, hatchedOne scale, both sides: full bar = 50%× = |realized| ÷ impliedSource: market data

Apr 15 '26

±17.0%

▼−6.25%

×0.37

Q1 FY26±32.1%▲+11.71%×0.36

TLXTelix Pharmaceuticals Ltd

9.10▼−4.28%· post 9.09

Mkt cap$3.1BRevenue—Revenue—

BZAIBlaize Holdings, Inc.

0.20▼−0.40%· post 0.20

ClosedOct 30 '26

Mkt cap$28.3MRevenue$12MQ2 FY26Revenue$39MFY25

Compare

ClosedOct 30 '26

TLXTelix Pharmaceuticals Ltd

BZAIBlaize Holdings, Inc.

9.10▼−4.28%post 9.09

Price

0.20▼−0.40%post 0.20

$3.1B

Mkt cap

$28.3M

—

Revenue

$12MQ2 FY26

—

Revenue

$39MFY25

TLX9.10▼−4.28%vsBZAI0.20▼−0.40%ClosedOct 30 '26